These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 29896103)
1. Characterization of the Differential Adverse Event Rates by Race/Ethnicity Groups for HPV Vaccine by Integrating Data From Different Sources. Huang J; Du J; Duan R; Zhang X; Tao C; Chen Y Front Pharmacol; 2018; 9():539. PubMed ID: 29896103 [TBL] [Abstract][Full Text] [Related]
4. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Wattigney WA; Mootrey GT; Braun MM; Chen RT Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733 [TBL] [Abstract][Full Text] [Related]
5. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308 [TBL] [Abstract][Full Text] [Related]
6. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194 [TBL] [Abstract][Full Text] [Related]
7. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013. Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101 [TBL] [Abstract][Full Text] [Related]
8. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016. Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003 [TBL] [Abstract][Full Text] [Related]
9. Advanced Clinical Decision Support for Vaccine Adverse Event Detection and Reporting. Baker MA; Kaelber DC; Bar-Shain DS; Moro PL; Zambarano B; Mazza M; Garcia C; Henry A; Platt R; Klompas M Clin Infect Dis; 2015 Sep; 61(6):864-70. PubMed ID: 26060294 [TBL] [Abstract][Full Text] [Related]
10. Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA. Jia Y; Zhu C; Du J; Xiang Y; Chen Y; Wang W; Tao C PeerJ; 2019; 7():e7490. PubMed ID: 31497391 [TBL] [Abstract][Full Text] [Related]
11. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). Niu MT; Rhodes P; Salive M; Lively T; Davis DM; Black S; Shinefield H; Chen RT; Ellenberg SS J Clin Epidemiol; 1998 Jun; 51(6):503-10. PubMed ID: 9635999 [TBL] [Abstract][Full Text] [Related]
12. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013. Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587 [TBL] [Abstract][Full Text] [Related]
13. A signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system data. Cai Y; Du J; Huang J; Ellenberg SS; Hennessy S; Tao C; Chen Y BMC Med Inform Decis Mak; 2017 Jul; 17(Suppl 2):76. PubMed ID: 28699543 [TBL] [Abstract][Full Text] [Related]
14. Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports. Guo W; Deguise J; Tian Y; Huang PC; Goru R; Yang Q; Peng S; Zhang L; Zhao L; Xie J; He Y Front Pharmacol; 2022; 13():870599. PubMed ID: 35814246 [TBL] [Abstract][Full Text] [Related]
15. Can the vaccine adverse event reporting system be used to increase vaccine acceptance and trust? Scherer LD; Shaffer VA; Patel N; Zikmund-Fisher BJ Vaccine; 2016 May; 34(21):2424-2429. PubMed ID: 27049120 [TBL] [Abstract][Full Text] [Related]
16. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018. Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795 [TBL] [Abstract][Full Text] [Related]
17. Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006-2017. Neha R; Subeesh V; Beulah E; Gouri N; Maheswari E Perspect Clin Res; 2020; 11(1):24-30. PubMed ID: 32154146 [TBL] [Abstract][Full Text] [Related]
18. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Braun MM; Mootrey GT; Salive ME; Chen RT; Ellenberg SS Pediatrics; 2000 Oct; 106(4):E51. PubMed ID: 11015546 [TBL] [Abstract][Full Text] [Related]
19. OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines. Zi W; Yang Q; Su J; He Y; Xie J Heliyon; 2022 Nov; 8(11):e11515. PubMed ID: 36411908 [TBL] [Abstract][Full Text] [Related]
20. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015. Haber P; Arana J; Pilishvili T; Lewis P; Moro PL; Cano M Vaccine; 2016 Dec; 34(50):6330-6334. PubMed ID: 27836437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]